Jacqulyne Robichaux works for MD Anderson Cancer Center. She receives funding from the NIH, CPRIT, Takeda Pharmaceuticals and Spectrum Pharmaceuticals. She is also an inventor on patents held by MD ...
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response PD-1 inhibition is effective in patients with ...
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results